William W Winder
Hearing Aid Provider in Provo, UT
License number
Utah 4806663-8914
Issued Date
Sep 26, 2000
Expiration Date
Sep 30, 2013
Category
xControlled Substance Handler
Type
Controlled Substance Handler Individual
Address
Address
Provo, UT
Personal information
See more information about William W Winder at radaris.comName
Address
Phone
368 S 200 E, Blanding, UT 84511
3826 W 8920 S, West Jordan, UT 84088
4943 S Murray Blvd APT Y34, Salt Lake City, UT 84123
612 Eastridge Dr, Tooele, UT 84074
2265 N 4575 W, Ogden, UT 84404
Professional information
Method Of Treatment Of Obesity And Paralyzed Muscle And Ergogenic Aids
US Patent:
2003021, Nov 13, 2003
Filed:
Dec 2, 2002
Appl. No.:
10/297117
Inventors:
William Winder - Provo UT, US
International Classification:
A61K031/7076
US Classification:
514/047000
Abstract:
The invention relates to a method of treating obesity in a mammal. The method includes the step of administering a therapeutically effective amount of an AMP-activated protein kinase activator to the mammal. The mammal may be for example, a human, a rat, a mouse, and the like. The AMP-activated protein kinase activator can be subcutaneously injected into the mammal or administered in any other manner that provides for uptake of the AMP-activated protein kinase activator into the cells of the mammal. The activation of the AMP-activated protein kinase activator can produce the benefits of exercise training including the loss of body fat. The invention also relates to a method of treating insulin resistance in a mammal suffering from obesity, type 2 diabetes, or muscle paralysis. To reduce the insulin resistance a therapeutically effective amount of an AMP-activated protein kinase activator is given to the mammal.
Use Of Amp Kinase Activators For Treatment Type 2 Diabetes And Insulin Resistance
US Patent:
2003021, Nov 13, 2003
Filed:
Dec 3, 2002
Appl. No.:
10/297114
Inventors:
William Winder - Provo UT, US
International Classification:
A61K031/7056, A61K031/7076
US Classification:
514/043000, 514/047000
Abstract:
A method of treating type 2 diabetes in a mammal is provided. The method includes the step of administering a therapeutically effective amount of an AMP-activated protein kinase activator to the mammal. The mammal may be for example, a human, a rat, a mouse, and the like. The AMP-activated protein kinase activator can be subcutaneously injected into the mammal or administered in any other manner that provides for uptake of the AMP-activated protein kinase activator into the cells of the mammal. The activation of the AMP-activated protein kinase activator can produce the benefits of exercise training including the translocation of GLUT4 in the muscle cells of the mammal. A method of treating insulin resistance in a mammal is also provided. To treat the insulin resistance a therapeutically effective amount of an AMP-activated protein kinase activator is given to the mammal.